Table 4.

Associations between HSPA1L–HSPA1A–HSPA1B genotypes and survival of patients with advanced NSCLC

GeneSNPsHazard ratio (95% CI)aPaLung cancer patientsDeathMST, moLog-rank P
Discovery setN = 330n = 257
 HSPA1L (+2763C>T)rs2075800
CC1.00 (Reference)140 (42.4)11111.7
CT0.79 (0.61–1.04)0.093149 (45.2)11315.00.124
TT0.87 (0.57–1.31)0.49541 (12.4)3320.20.153
 HSPA1L (+2437A>G)rs2227956
AA1.00 (Reference)185 (56.1)14414.2
AG1.08 (0.83–1.40)0.586117 (35.5)9412.90.676
GG0.75 (0.46–1.23)0.25728 (8.5)1922.80.130
 HSPA1A (−110A>C)rs1008438
AA1.00 (Reference)118 (35.8)8418.0
AC1.15 (0.86–1.54)0.345155 (47.0)12613.40.047
CC1.37 (0.95–1.98)0.09257 (17.3)4711.20.009
 HSPA1A (+190G>C)rs1043618
GG1.00 (Reference)167 (50.6)12317.0
GC1.13 (0.87–1.48)0.363139 (42.1)11513.30.013
CC1.11 (0.67–1.84)0.68524 (7.3)1911.70.237
 HSPA1B (−912C>T)rs2763979
CC1.00 (Reference)183 (55.5)13216.5
CT1.43 (1.10–1.87)0.008120 (36.4)10312.20.011
TT1.80 (1.13–2.85)0.01327 (8.2)2212.70.031
 HSPA1B (+39C>T)rs6457452
CC1.00 (Reference)291 (88.2)22614.5
CT + TT1.51 (1.04–2.21)0.03239 (11.8)3110.70.025
Validation set
 HSPA1B (−912C>T)rs2763979N = 325n = 239
CC1.00 (Reference)142 (43.7)10718.6
CT1.00 (0.75–1.32)0.982150 (46.2)10616.80.948
TT1.61 (1.03–2.52)0.03633 (10.2)2615.00.270
 HSPA1B (+39C>T)rs6457452N = 323n = 236
CC1.00 (Reference)256 (79.3)19217.3
CT + TT0.79 (0.56–1.10)0.16167 (20.7)4421.40.133
Pooled analysis
 HSPA1B (−912C>T)rs2763979N = 655n = 496
CC1.00 (Reference)325 (49.6)23917.8
CT1.21 (1.00–1.46)0.045270 (41.2)20915.00.128
TT1.66 (1.21–2.27)0.00260 (9.2)4814.20.026

NOTE: The frequency of rs6457452TT genotype was 0.6% (2 of 322) and 2.2% (7 of 313) in the discovery and validation sets respectively; therefore, we combined rs6457452CT with rs6457452TT for analyses.

  • aThe Cox regression analysis was adjusted for age, sex, pack-years smoked, histology, TNM stage, surgical operation, chemotherapy, and radiotherapy status.